Results 1 to 10 of about 1,390 (143)

Antithrombotic Therapy in Elderly Patients with Atrial Fibrillation: The State of the Problem in the Real Clinical Practice of a Family Medicine Doctor

Acta Biomedica Scientifica, 2021
Introduction. The research aimed at studying the efficacy and safety of anticoagulant therapy in patients with atrial fibrillation (AF), especially in older age groups, is now increasingly relevant.The aim of the study is to analyze the situation with ...
Bazira Kanat кyzy, N. K. Kinderbaeva, S. O. Turdaliyev, Zh. A. Mahmudova, U. K. Kundashev, S. M. Mamatov   +5 more
doaj   +1 more source

EFFECT OF LONG-TERM ENOXAPARIN THERAPY ON RISK OF RECURRENT VENOUS THROMBOEMBOLIC COMPLICATIONS AND RECANALIZATION OFTHROMBOSED VEINS

Атеротромбоз, 2015
The article presents the results of its own study of the effect of long-term (not less than 30 days) enoxa-parin therapy (1 mg/kg administered subcutaneously every 12h) on the risk of recurrent venous thromboembolic complications (VTC) and recanalization
N. M. Vorobyova, O. V. Ermolina, T. V. Balakhonova, A. I. Kiriyenko, E. P. Panchenko   +4 more
doaj   +1 more source

Oral anticoagulants in the prevention of thromboembolic complications in cardiac patients: analysis of use in the Russian Federation

Качественная клиническая практика, 2020
In last years, special attention has been paid in the Russian Federation (RF) to improving medical care for patients with atrial fibrillation (AF) and the prevention of thromboembolic complications (TEC).
A. A. Gruzdeva, A. A. Khokhlov, M. V. Ilyin   +2 more
doaj   +1 more source

PHARMACOECONOMIC EVALUATION OF DABIGATRAN VS WARFARIN IN CARDIOVASCULAR EVENTS PREVENTION IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION

Рациональная фармакотерапия в кардиологии, 2015
According to recent guidelines, oral dabigatran etexilate is indicated for stroke and systemic embolism prevention in patients with atrial fibrillation (AF). Aim.
Yu. B. Belousov, V. Yu. Mareev, I. S. Yavelov, D. Yu. Belousov   +3 more
doaj   +1 more source

FREQUENCIES OF POLYMORPHISMS IN THE CYTOCHROME’S P450 GENES OF WARFARIN TRANSFORMATION IN A EUROPEAN POPULATION OF EASTERN SIBERIA

Acta Biomedica Scientifica, 2018
Background. Genotypes of the cytochrome p450 isoform (CYP2C9 and CYP4F2) determine warfarin dose requirements. Frequencies of risk alleles and genotypes of CYP2C9 and CYP4F2 gene vary in different races and ethnic groups.Aim.
T. A. Bairova, E. A. Novikova, F. I. Belyalov, E. A. Shchedreeva, K. D. Ievleva, O. V. Kalyuzhnaya, O. A. Ershova, V. G. Pustozerov, O. A. Kovaleva, I. V. Rasputina, I. A. Noskova, T. V. Batogova, O. V. Kuznetsova, O. Yu. Bogoslova, S. I. Kolesnikov   +14 more
doaj   +1 more source

DABIGATRAN ETEXILATE FOR THE TREATMENT OF VENOUS THROMBOEMBOLIC COMPLICATIONS

Атеротромбоз, 2015
This article discusses the significant features and use of new oral anticoagulant dabigatran etexilate for the treatment of venous thromboembolic complications (VTC).
N. M. Vorobieva, E. P. Panchenko
doaj   +1 more source

ANALYSIS OF THE INFLUENCE OF THROMBOEMBOLIC COMPLICATIONS PREVENTION WITH ORAL ANTICOAGULANTS ON BUDGET IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION

Рациональная фармакотерапия в кардиологии, 2015
Atrial fibrillation (AF) is a risk factor for thromboembolic complications, requiring administration of vitamin K antagonists (warfarin) or the new oral anticoagulants (apixaban, dabigatran and rivaroxaban).Aim. To assess the influence of apixaban use on
A. V. Rudakova
doaj   +1 more source

COST-EFFECTIVENESS OF APIXABAN AS COMPARED WITH WARFARIN AND ACETYLSALICYLIC ACID IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION IN THE RUSSIAN FEDERATION

Рациональная фармакотерапия в кардиологии, 2015
Background. For prevention of thromboembolic events in patients with non-valvular atrial fibrillation (NVAF) the following types of antithrombotic therapy are used: anticoagulant therapy with vitamin K antagonists (such as warfarin), antiplatelet therapy
A. V. Rudakova, V. A. Parfenov
doaj   +1 more source

Warfarin and its role in the prevention of thromboembolism in atrial fibrillation (lecture)

Медицинский совет, 2015
In the article "Antithrombotic therapy in atrial fibrillation: new oral anticoagulants" (Meditsinskiy Sovet, 2014, P. 38--48), the focus was on direct thrombin inhibitors and factor Xa inhibitors. This is quite justified.
Y. V. Shubik
doaj   +1 more source

Anticoagulants in clinical practice. The place of vitamin K antagonists in combination with new oral anticoagulants

Медицинский совет, 2015
Thrombotic and thromboembolic complications are associated with activation of blood coagulation and local thrombosis in different parts of the vascular bed.
T. V. Vavilova
doaj   +1 more source